PMDD · 7 min read · 2026-05-16
Magnesium Glycinate for PMDD: GABA Modulation, Prostaglandin Regulation, and RCT Evidence
Magnesium is a divalent cation serving as cofactor for more than 300 enzymatic reactions and as an endogenous NMDA receptor antagonist and GABA-A receptor modulator. Deficiency is among the most prevalent micronutrient deficiencies in developed nations (~70% population below recommended intake), and its relevance to PMDD and primary dysmenorrhea is well-established through both mechanistic biology and controlled clinical evidence. This review examines the neurological, neuroendocrine, and reproductive mechanisms, RCT evidence, and the clinical rationale for the glycinate chelate specifically.
Neurological Mechanisms: GABA Modulation and NMDA Antagonism
[Image: Neuronal receptor diagram: magnesium ion blocking NMDA channel pore; GABA-A receptor with Mg2+ as co-agonist increasing Cl− influx]
Magnesium's central nervous system effects operate through two primary ion channel mechanisms. First, magnesium is a co-agonist at GABA-A receptors — it potentiates chloride channel opening in response to GABA binding, amplifying inhibitory neurotransmission. PMDD pathophysiology involves abnormal sensitivity to normal GABA-A receptor modulation by allopregnanolone (a progesterone metabolite), with paradoxical excitatory responses during the luteal phase. Magnesium's potentiation of GABA-A activity represents a complementary intervention that does not depend on allopregnanolone signaling.
Second, magnesium serves as the physiological NMDA receptor blocker — occupying the channel pore at resting potential and preventing calcium influx. Hypomagnesemia lowers this blocking efficiency, increasing NMDA-mediated excitatory neurotransmission and neural hyperexcitability, contributing to anxiety, irritability, and hyperalgesia. This mechanism directly connects magnesium deficiency to the mood symptom cluster of PMDD.
Serotonin and HPA Axis: Magnesium as Cofactor
Magnesium is a required cofactor for tryptophan hydroxylase, the rate-limiting enzyme in serotonin biosynthesis (tryptophan → 5-HTP → serotonin). Marginal magnesium deficiency reduces serotonin synthetic capacity — providing a biochemical link between deficiency and mood disorders, particularly conditions with serotonergic dysregulation like PMDD.
Additionally, magnesium modulates HPA axis reactivity. Magnesium-deficient animals show exaggerated ACTH and cortisol responses to acute stress, and magnesium supplementation attenuates these responses. In humans, elevated cortisol further depletes magnesium through increased renal excretion (cortisol reduces magnesium reabsorption in the loop of Henle), establishing a bidirectional stress-deficiency cycle that is particularly relevant to the luteal phase, when progesterone-mediated stress sensitivity is heightened.
Prostaglandin Regulation and Dysmenorrhea Mechanism
[Image: Arachidonic acid pathway showing magnesium inhibiting COX enzyme, reducing PGF2α → uterine contraction]
Primary dysmenorrhea is driven by excess endometrial prostaglandin E2 (PGE2) and F2α (PGF2α) production in the luteal phase, causing myometrial hypercontractility and vasoconstriction. Magnesium inhibits prostaglandin synthesis through two mechanisms:
1. Inhibition of cyclooxygenase (COX) enzyme activity — magnesium acts as a competitive inhibitor at the arachidonic acid binding site of COX-1 and COX-2, reducing thromboxane and prostaglandin production 2. Direct smooth muscle relaxation — magnesium competes with calcium at voltage-gated calcium channels in myometrial smooth muscle. Calcium influx triggers myometrial contraction; magnesium blocks this influx, promoting relaxation
This dual mechanism explains why magnesium's analgesic effect in dysmenorrhea is both preventive (prostaglandin reduction if dosed in the premenstrual phase) and acute (smooth muscle relaxation during menstruation).
RCT Evidence: PMDD, PMS, and Dysmenorrhea
Facchinetti et al. (1991, Obstetrics & Gynecology, n=32, double-blind crossover) compared magnesium pyrrolidone carboxylic acid (360mg elemental/day) to placebo over two cycles in PMS patients. Magnesium significantly reduced total PMR scale scores (p<0.05), with the most pronounced effects on mood symptoms (anxiety, tension, irritability) — consistent with the GABA/NMDA mechanism. Physical symptoms including breast tenderness and weight gain also improved.
Walker et al. (1998, Journal of Women's Health, n=44) combined magnesium 200mg/day with vitamin B6 in PMS patients, finding combined treatment superior to either alone — suggestive of synergistic effects (B6 is required for pyridoxal phosphate-dependent serotonin synthesis, potentially additive with magnesium's tryptophan hydroxylase cofactor role).
For dysmenorrhea specifically, Zekavat et al. (2015, Iranian Journal of Nursing and Midwifery Research) compared magnesium supplementation to ibuprofen in a crossover RCT. Magnesium reduced dysmenorrhea pain scores with an effect size approximately 60% of ibuprofen but with a sustained benefit extending beyond the treatment cycle — consistent with COX pathway modulation rather than acute analgesic action.
Form Selection, Bioavailability, and Dosing
Magnesium salt bioavailability varies substantially:
• Magnesium oxide: ~4% absorption. Despite high elemental content (~60%), the minimal bioavailability renders it clinically ineffective for deficiency correction beyond laxative use. • Magnesium citrate: ~30% absorption. Well-studied, effective; mild laxative effect at higher doses limits tolerable dose. • Magnesium glycinate (bisglycinate): ~30-50% absorption with superior tolerability. The glycine chelation protects magnesium from competitive intestinal absorption inhibition by phosphates and oxalates. Additionally, glycine itself is an inhibitory neurotransmitter acting at glycine receptors and as a co-agonist at NMDA receptors — providing independent anxiolytic and sleep-promoting effects that are additive with magnesium's CNS mechanisms.
Clinical protocol for PMDD/dysmenorrhea: • Form: magnesium bisglycinate preferred • Dose: 300mg elemental magnesium at bedtime (note: elemental content ~14% of bisglycinate salt weight — a 2g bisglycinate capsule contains ~280mg elemental) • Timing: evening dosing maximizes sleep benefit; premenstrual phase loading (increase to 400mg days 14-28) may amplify dysmenorrhea prevention • Duration: minimum 3 menstrual cycles for full assessment; tissue repletion of chronic deficiency requires 4-6 weeks
The bottom line
Magnesium glycinate addresses PMDD through three mechanistically distinct and well-characterized pathways: GABA-A potentiation and NMDA antagonism for mood and anxiety, serotonin synthesis cofactor activity for luteal-phase mood regulation, and prostaglandin/calcium channel modulation for dysmenorrhea. RCT evidence across multiple formulations is consistent and directionally robust. The pervasiveness of dietary magnesium deficiency means that a significant proportion of PMDD patients are effectively self-limiting their neurological stress resilience and inflammatory regulation. Magnesium glycinate is the most clinically appropriate formulation, combining superior bioavailability with independent glycine-mediated CNS benefits.
Questions
Is magnesium glycinate the same as magnesium bisglycinate?
Yes — bisglycinate refers to the chelation of one magnesium ion with two glycine molecules. Both terms are used interchangeably in the supplement literature. Bisglycinate is technically more precise (one Mg²⁺, two glycinate ligands), and products standardized to bisglycinate typically have the most reliable elemental content per capsule.
Should magnesium be cycled or taken continuously for PMDD?
Continuous daily supplementation is appropriate given the prevalence of baseline deficiency and the ongoing magnesium requirements of the HPA axis and reproductive system. A premenstrual phase loading approach (increasing dose in the luteal phase) may provide additional targeted benefit for dysmenorrhea and luteal mood symptoms, though this has not been directly compared to continuous dosing in RCTs.
Does magnesium supplementation affect thyroid function?
Magnesium is a cofactor for thyroid peroxidase (TPO), the enzyme that synthesizes thyroid hormones. Deficiency may impair thyroid hormone synthesis. Supplementation at standard doses (300mg/day) does not suppress thyroid function. For women with subclinical hypothyroidism and magnesium deficiency — a clinically relevant combination given the overlap with PMDD symptoms — correcting magnesium status may have a modest beneficial effect on thyroid function.
What is the evidence for combining magnesium with vitamin B6 specifically?
Vitamin B6 (pyridoxal phosphate) is a required cofactor for aromatic L-amino acid decarboxylase (DOPA decarboxylase), which converts 5-HTP to serotonin and L-DOPA to dopamine. B6 is also required for the synthesis of GABA from glutamate via GAD (glutamic acid decarboxylase). These pathways are complementary to magnesium's tryptophan hydroxylase cofactor role and GABA-A modulation. The Walker (1998) RCT showing superiority of combination therapy supports synergism, though the individual contributions were not isolated.
What is the tolerable upper intake level for supplemental magnesium, and is 300mg/day safe?
The NOAEL (no observed adverse effect level) established tolerable upper intake level for supplemental magnesium (not dietary) is 350mg/day elemental for adults. At 300mg/day elemental, the standard protocol for PMDD is within this limit. The adverse effect at excess doses is osmotic diarrhea, not systemic toxicity. Individuals with CKD require medical supervision as impaired renal excretion of magnesium creates hypermagnesemia risk.
Build an evidence-based PMDD protocol.
Selene's personalization engine maps your hormonal profile to peer-reviewed ingredient stacks, adjusted for your cycle phase and symptom cluster.
View the PMDD clinical profile →